Please Wait
Applying Filters...
menu
    • menu
    Polpharma is a Polish CDMO of APIs and a significant European API producer, delivering products to companies worldwide.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    Polfa Tarchomin is a leading Polish pharmaceutical company with 200 year tradition in manufacture and sale of pharmaceutical products.

    Virtual Booth

    Contact Supplier

    LGM Pharma accelerates & optimizes the new product pathway from early development through commercialization.

    Virtual Booth

    Contact Supplier

    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    jdmfs-not-supported-m-2025-04-28

    Virtual Booth

    An Enquiry

    Menu

    Aramchol

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,987Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Galmed: Aramchol Boosts Bayer's Regorafenib in GI Cancer Models
    Galmed: Aramchol Boosts Bayer's Regorafenib in GI Cancer Models

    06 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-announces-first-time-results-in-oncology-studies-aramchol-significantly-enhances-bayers-regorafenib-effect-in-gi-cancer-models-302447161.html

    PR NEWSWIRE
    06 May 2025
    Share Share
    Galmed Pharmaceuticals & VCU Collab on Drug Resistance GI Cancer
    Galmed Pharmaceuticals & VCU Collab on Drug Resistance GI Cancer

    17 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-launches-vcu-collaboration-to-tackle-drug-resistance-in-gi-cancers-302431484.html

    PR NEWSWIRE
    17 Apr 2025
    Share Share
    Galmed Reveals New Blood Markers for Aramchol, Advanced SCD1 Inhi
    Galmed Reveals New Blood Markers for Aramchol, Advanced SCD1 Inhi

    15 Apr 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-unveils-novel-pharmacodynamic-blood-markers-for-aramchol-the-most-clinically-advanced-scd1-inhibitor-302428834.html

    PR NEWSWIRE
    15 Apr 2025
    Share Share
    Galmed Pharmaceuticals Extends Aramchol Patent Protection to 2039
    Galmed Pharmaceuticals Extends Aramchol Patent Protection to 2039

    20 Mar 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-pharmaceuticals-secures-new-patent-grant-extending-aramchols-patent-protection-to-2039-strengthening-leadership-in-nashmash-combination-therapy-302407043.html

    PR NEWSWIRE
    20 Mar 2025
    Share Share
    Galmed reports results from ARMOR study showing improvements
    Galmed reports results from ARMOR study showing improvements

    04 Jan 2023

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-reports-results-from-the-open-label-part-of-the-armor-study-showing-improvements-in-histology-imaging-and-biomarkers-with-aramchol-301713284.html

    PR NEWSWIRE
    04 Jan 2023
    Share Share
    Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in Lung Fibrosis
    Galmed Reports Significant Anti-Fibrotic Effects of Aramchol in Lung Fibrosis

    07 Jul 2022

    // PRNEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-reports-significant-anti-fibrotic-effects-of-aramchol-in-a-lung-fibrosis-model-301582307.html

    PRNEWSWIRE
    07 Jul 2022
    Share Share